This article is more than 5 years old. Information may no longer be current.

Eylea drives increase in net income for Regeneron

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Regeneron Pharmaceuticals reported a net income of $750.3 million in 2012, compared with a net loss of $221.8 million in 2011, according to a company press release.

Revenues increased from $445.8 million in 2011 to $1.4 billion in 2012. Eylea (aflibercept) accounted for $838 million in U.S. net sales in 2012, leading to Regeneron’s first full year of profitability, according to the release.

U.S. net sales of Eylea are predicted to be $1.2 billion to $1.3 billion in 2013. Regeneron partner Bayer Healthcare has launched Eylea for the treatment of neovascular age-related macular degeneration in Japan, Europe, Australia and elsewhere, according to the release.

In the fourth quarter, Regeneron reported a net income of $470.4 million compared with a net loss of $53.4 million the previous year.

Revenues for the quarter totaled $414.6 million, up from $123 million in 2011, while expenses increased to $268.9 million from $168.4 million in 2011.